Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Biological responses to environmental effects are mediated through epigenetic changes such as chemical modifications of the histone tails and DNA (5-cytosine) methylation. We report that dietary protein restriction in pregnant mice can alter histone modifications in the promoter region of the Igf2 gene and cause a two-fold repression in promoter specific Igf2 transcription in the liver of the fetus. Suppression of Igf2 is accompanied with low birth weight of the pups born to the protein-restricted dams. Our results provide new information about the epigenetic aspects of early life programming and will improve our understanding about the developmental origins of adult diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/nass/nrm063 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prediction of Fetal Growth Restriction Using Serum PlGF Combined with PAPP-A in Early Pregnancy.
Int J Womens Health
September 2025
Department of Obstetrics, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, People's Republic of China.
Objective: This study aimed to assess the predictive capacity of placenta growth factor (PlGF) and pregnancy-associated plasma protein-A (PAPP-A) levels in the serum of pregnant women during early pregnancy (11-13 weeks) for fetal growth restriction (FGR).
Patients And Methods: A retrospective cohort study was conducted involving 1602 pregnant women who gave birth at The Second Nanning People's Hospital between March 2018 and September 2019. Serum concentrations of PlGF and PAPP-A were measured during early pregnancy for all participants.
Time restricted eating and exercise training before and during pregnancy for people with increased risk of gestational diabetes: single centre randomised controlled trial (BEFORE THE BEGINNING).
BMJ
September 2025
Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway.
Objective: To determine the effect of a prepregnancy lifestyle intervention on glucose tolerance in people at higher risk of gestational diabetes mellitus.
Design: Single centre randomised controlled trial (BEFORE THE BEGINNING).
Setting: University hospital in Trondheim, Norway.
Navigating Hepatitis C care: Knowledge gaps and access barriers among young women who inject drugs in rural Appalachia.
PLoS One
September 2025
Wake Forest University School of Medicine, Department of Implementation Science, Winston-Salem, North Carolina, United States of America.
Background: Hepatitis C virus (HCV) and injection drug use among young women are dramatically rising in the rural United States. From 2004 to 2017, heroin use among non-pregnant women increased 22.4% biennially, mirroring increases in HCV cases, especially among younger populations.
View Article and Find Full Text PDFLevels of placental extracellular vesicles predicts fetal growth restriction and fetal distress in established severe pre-eclampsia.
Int J Gynaecol Obstet
September 2025
Department of Gynecology and Obstetrics, Tianjin Key Laboratory of Female Reproductive Health and Eugenics, Tianjin Medical University General Hospital, Tianjin, China.
Objective: To evaluate whether plasma levels of placental extracellular vesicles (pcEVs), the EV-scavenging factor lactadherin, and prothrombotic markers predict fetal growth restriction (FGR) and/or fetal distress (FD) in established severe pre-eclampsia (sPE).
Methods: We recruited 80 sPE patients, 41 normal pregnancies, and 27 non-pregnant women. SPE patients were further dichotomized into event and non-event groups based on the occurrence of FGR/FD during a follow-up period of 77 days.
Opioid agonist therapy for opioid use disorder in primary versus specialty care.
Cochrane Database Syst Rev
September 2025
Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada.
Background: Opioid use disorder (OUD) is commonly treated in specialized care settings with long-acting opioid agonists, also known as opioid agonist therapy, or OAT. Despite the rise in opioid use globally and evidence for a 50% reduction in mortality when OAT is employed, the proportion of people with OUD receiving OAT remains small. One initiative to improve the access and uptake of OAT could be to offer OAT in a primary care setting; primary care clinics are more numerous, might reduce the visibility and potential stigma of receiving treatment for OUD, and may facilitate the care of other medical conditions that are unrelated to OUD.
View Article and Find Full Text PDF